Medicine@Yale

As interest resurges in the therapeutic potentials of psychedelic drugs such as psilocybin, made from the active ingredient in so-called magic mushrooms, the Yale Program for Psychedelic Science has been at the forefront of studying these promising new therapies for treating mental illness.

This result highlights the importance of studying ASD in females rather than assuming that what is true for mostly male study populations also applies to females.

Damage to nerves of the brain and spinal cord is particularly devastating because these nerves do not grow back on their own. Perhaps, suggests a Yale-led study, they could regrow with a little help from science.

The center will have an ambitious goal: to produce better diagnoses, treatments, and ultimately cures for these diseases. It will also work toward vaccine development.

Seventeen years after it began, in 2005, publication of Medicine@Yale is coming to an end with this issue.

In his new role, Winer is working to promote paradigm-changing dis- covery and to build an unparalleled clinical program that offers seamless, multidisciplinary care and clinical trials to all patients, eliminating dis- parities in access, care, and outcomes.

To have the juxtaposition of being at an institution with such a rich history, but one that can, and wants to, move forward is very special, she says.

Isaac Y. Kim, MD, PhD, MBA, was appointed chair of the Department of Urology at Yale School of Medicine (YSM) and chief of Urology at Yale New Haven Hospital.

McGovern will participate actively in the senior leadership group of the medical school’s academic health system and play a key role in setting and realizing strategic goals. As deputy dean for clinical affairs, she will serve as the physician leader who represents the clinical mission of the School of Medicine in all venues.

Made the cancer hospital that bears his name possible with a generous gift in 2007